Corvus Pharmaceuticals Unveils Promising Interim Results from Phase 1 Trial of Soquelitinib for Atopic Dermatitis

Reuters

06-04

Corvus Pharmaceuticals Unveils Promising Interim Results from Phase 1 Trial of Soquelitinib for Atopic Dermatitis

Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, has announced new interim data from its Phase 1 clinical trial of soquelitinib for moderate to severe atopic dermatitis. The trial is randomized, double-blind, and placebo-controlled, focusing on 48 patients across three cohorts. Cohort 3, receiving 200 mg twice daily, showed earlier and deeper responses compared to cohorts 1 and 2. At day 28, cohort 3 demonstrated a 64.8% mean reduction in the Eczema Area and Severity Index $(EASI)$ score, compared to 54.6% for cohorts 1 and 2 combined, and 34.4% for the placebo group. The company has also initiated an extension cohort study exploring the cohort 3 dose over an 8-week period. Dr. Miller is set to present the findings at the Jefferies Global Healthcare Conference on June 5, 2025, with the presentation available via webcast on the Corvus website.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corvus Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-25-003661), on June 04, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2540467050"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2540467050\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2540467050?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-04 19:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2540467050","market":"us","top_or_hot":-1,"title":"Corvus Pharmaceuticals Unveils Promising Interim Results from Phase 1 Trial of Soquelitinib for Atopic Dermatitis","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Corvus Pharmaceuticals Unveils Promising Interim Results from Phase 1 Trial of Soquelitinib for Atopic Dermatitis\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CRVS\">Corvus Pharmaceuticals, Inc.</a>, a clinical-stage biopharmaceutical company, has announced new interim data from its Phase 1 clinical trial of soquelitinib for moderate to severe atopic dermatitis. The trial is randomized, double-blind, and placebo-controlled, focusing on 48 patients across three cohorts. Cohort 3, receiving 200 mg twice daily, showed earlier and deeper responses compared to cohorts 1 and 2. At day 28, cohort 3 demonstrated a 64.8% mean reduction in the Eczema Area and Severity Index <a href=\"https://laohu8.com/S/EASI\">$(EASI)$</a> score, compared to 54.6% for cohorts 1 and 2 combined, and 34.4% for the placebo group. The company has also initiated an extension cohort study exploring the cohort 3 dose over an 8-week period. Dr. Miller is set to present the findings at the Jefferies Global Healthcare Conference on June 5, 2025, with the presentation available via webcast on the Corvus website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corvus Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-25-003661), on June 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Corvus Pharmaceuticals Unveils Promising Interim Results from Phase 1 Trial of Soquelitinib for Atopic Dermatitis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCorvus Pharmaceuticals Unveils Promising Interim Results from Phase 1 Trial of Soquelitinib for Atopic Dermatitis\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-04 19:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Corvus Pharmaceuticals Unveils Promising Interim Results from Phase 1 Trial of Soquelitinib for Atopic Dermatitis\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CRVS\">Corvus Pharmaceuticals, Inc.</a>, a clinical-stage biopharmaceutical company, has announced new interim data from its Phase 1 clinical trial of soquelitinib for moderate to severe atopic dermatitis. The trial is randomized, double-blind, and placebo-controlled, focusing on 48 patients across three cohorts. Cohort 3, receiving 200 mg twice daily, showed earlier and deeper responses compared to cohorts 1 and 2. At day 28, cohort 3 demonstrated a 64.8% mean reduction in the Eczema Area and Severity Index <a href=\"https://laohu8.com/S/EASI\">$(EASI)$</a> score, compared to 54.6% for cohorts 1 and 2 combined, and 34.4% for the placebo group. The company has also initiated an extension cohort study exploring the cohort 3 dose over an 8-week period. Dr. Miller is set to present the findings at the Jefferies Global Healthcare Conference on June 5, 2025, with the presentation available via webcast on the Corvus website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corvus Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-25-003661), on June 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nNDL4wNLXy:1","article_id":"2540467050","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2540467050","pubTimestamp":1749034868,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, has announced new interim data from its Phase 1 clinical trial of soquelitinib for moderate to severe atopic dermatitis. The trial is randomized, double-blind, and placebo-controlled, focusing on 48 patients across three cohorts. Cohort 3, receiving 200 mg twice daily, showed earlier and deeper responses compared to cohorts 1 and 2. At day 28, cohort 3 demonstrated a 64.8% mean reduction in the Eczema Area and Severity Index  score, compared to 54.6% for cohorts 1 and 2 combined, and 34.4% for the placebo group. The company has also initiated an extension cohort study exploring the cohort 3 dose over an 8-week period. Dr. Miller is set to present the findings at the Jefferies Global Healthcare Conference on June 5, 2025, with the presentation available via webcast on the Corvus website.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Corvus Pharmaceuticals公布了索奎替尼治疗特应性皮炎1期试验的有希望的中期结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRVS":0.9},"content_text":"Corvus Pharmaceuticals Unveils Promising Interim Results from Phase 1 Trial of Soquelitinib for Atopic Dermatitis\n    \n\nCorvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, has announced new interim data from its Phase 1 clinical trial of soquelitinib for moderate to severe atopic dermatitis. The trial is randomized, double-blind, and placebo-controlled, focusing on 48 patients across three cohorts. Cohort 3, receiving 200 mg twice daily, showed earlier and deeper responses compared to cohorts 1 and 2. At day 28, cohort 3 demonstrated a 64.8% mean reduction in the Eczema Area and Severity Index $(EASI)$ score, compared to 54.6% for cohorts 1 and 2 combined, and 34.4% for the placebo group. The company has also initiated an extension cohort study exploring the cohort 3 dose over an 8-week period. Dr. Miller is set to present the findings at the Jefferies Global Healthcare Conference on June 5, 2025, with the presentation available via webcast on the Corvus website.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corvus Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-25-003661), on June 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}